Abstract
Biologic and targeted small-molecule therapies have revolutionized the management of severe asthma by specifically targeting key inflammatory pathways. These advances have led to significant reductions in exacerbations, improved lung function, and decreased dependence on corticosteroids. However, a substantial number of patients still experience breakthrough exacerbations and inadequate disease control, indicating that there are residual inflammatory mechanisms beyond the classical type-2 pathways. Current biologics that target immunoglobulin E, interleukin-5, interleukin-4 receptor alpha, and thymic stromal lymphopoietin show efficacy in biomarker-defined populations. Yet, their clinical benefits are closely tied to baseline type-2 biomarkers, and they often fall short for patients with non-type-2 or mixed inflammatory phenotypes. Emerging evidence from transcriptomic and clinical studies suggests that factors such as epithelial dysfunction, innate immune activation, and tissue repair pathways contribute to ongoing disease instability, even with targeted cytokine blockade. These insights have spurred the development of new therapeutic strategies, including biologics aimed at upstream epithelial alarmins like interleukin-33, oral small-molecule inhibitors such as Bruton tyrosine kinase inhibitors, lineage-directed eosinophil-suppressing agents, inhaled biologics, and nanobody-based therapies. Additionally, long-acting and ultra- long-acting biologics are designed to enhance treatment durability and adherence, while bispecific antibodies integrate both upstream and downstream inflammatory inhibition into a single molecular construct. These advancements signify a shift towards broader and more sustained modulation of inflammatory pathways. Future progress in asthma treatment will hinge on integrating insights from epithelial biology, refining biomarker- guided patient selection, and developing multispecific and upstream-targeting therapies to address persistent disease heterogeneity and improve long-term clinical outcomes.
Keywords: Asthma, Severe; Biological Products; Alarmins; Eosinophils; Biomarkers
Key Figure

Background
Asthma is a highly heterogeneous chronic respiratory condition characterized by episodic airflow limitation, persistent airway inflammation, and an increased risk of acute exacerbations, even with intensive inhaled therapy [1]. Although inhaled therapy combining inhaled corticosteroids (ICSs), long-acting β2-agonists (LABAs), and/or long-acting muscarinic antagonists (LAMAs) has shown a reduction in exacerbation risk, many asthma patients continue to experience poor disease control. These limitations have prompted a growing interest in clinical remission as a promising treatment target, with evidence suggesting that achieving remission is associated with slower lung function decline and a reduced risk of exacerbations in asthma [2,3]. Biologic therapies that target canonical type-2 inflammatory pathways, including immunoglobulin E (IgE), interleukin (IL)-5, the IL-5 receptor, IL-4Rα, and thymic stromal lymphopoietin (TSLP), have transformed the management of severe asthma by reducing exacerbations and minimizing the need for systemic corticosteroids [4]. Despite these advances, a significant subset of treated patients continues to experience breakthrough exacerbations and incomplete control. This reflects residual inflammatory activity and clinical heterogeneity that extend beyond traditional type-2-driven mechanisms [5,6]. Detailed analyses of exacerbations during anti-IL-5 therapy indicate that persistent attacks can arise from both eosinophilic and non-eosinophilic profiles, highlighting the limitations of single-axis cytokine blockade. Meanwhile, emerging biologic agents targeting upstream epithelial alarmins have demonstrated potential in reducing exacerbations across a wider range of inflammatory phenotypes, including patients with low eosinophil counts [7,8]. These observations highlight both the progress made and the ongoing unmet needs in asthma management, underscoring the need for novel therapeutic strategies that go beyond traditional monoclonal antibody biologics. This review focuses on emerging biologic agents that target upstream epithelial pathways, as well as oral small-molecule therapies such as Bruton tyrosine kinase (BTK) inhibitors and lineage- directed compounds. Many of these therapies act within upstream alarmin or type-2 signaling cascades but offer mechanistically distinct or broader approaches compared to currently approved treatments. This narrative review is based on a search of PubMed and ClinicalTrials.gov, supplemented by major respiratory conference proceedings from the American Thoracic Society and European Respiratory Society, covering publications up to February 2026. Agents were selected based on the availability of phase 2 or higher clinical trial data or their mechanistic novelty related to emerging therapeutic strategies. Abstract-only conference data were included selectively when peer-reviewed publications were not available.
Optimizing Inhaled Therapy before Biologics
Before escalating to biologic therapy, optimizing inhaled treatments is a critical step for patients with uncontrolled asthma. Inadequate control may indicate suboptimal pharmacologic coverage rather than true biologic refractoriness. When defining severe asthma, it is essential to ensure that potentially modifiable factors—such as inhaler technique, treatment adherence, and comorbidity management—have been adequately addressed before attributing poor control to refractory disease. For patients with moderate-to-severe asthma, adding a LAMA to ICS and LABA has been shown to improve lung function and reduce the risk of exacerbations in those with persistent symptoms [9]. Subsequent development of fixed-dose triple inhaler regimens combining ICS, LABA, and LAMA has enabled the consistent delivery of three complementary bronchodilatory and anti-inflammatory mechanisms in a single device [10]. A large systematic review and meta-analysis of randomized controlled trials demonstrated that triple therapy significantly improved trough forced expiratory volume in 1 second (FEV1) and reduced moderate-to-severe exacerbations compared to ICS/LABA therapy in patients with uncontrolled asthma [11]. Importantly, the benefits of triple therapy were consistent across a wide range of baseline lung function and symptom severity, reinforcing its role as an intermediate escalation step before initiating biologic treatment. Clinical trials evaluating single inhaler triple therapy have further shown that improvements in lung function can be achieved without a proportional increase in ICS exposure, partly due to optimized particle deposition and enhanced airway delivery [12]. Therefore, inadequate asthma control does not always indicate a need for biologic therapy; instead, optimizing inhaled regimens may lead to clinically meaningful improvements for a significant subset of patients [13]. The approved and investigational targeted therapies discussed in this review are summarized in Table 1.
Table 1.
Summary of approved and investigational targeted therapies for severe asthma
| Agent | Target | Modality | Development stage | Key trial | Population |
|---|---|---|---|---|---|
| Omalizumab | IgE | mAb | Approved | INNOVATE | Allergic asthma |
| Mepolizumab | IL-5 | mAb | Approved | MENSA | Eosinophilic asthma |
| Benralizumab | IL-5Rα | mAb | Approved | SIROCCO | Eosinophilic asthma |
| Dupilumab | IL-4Rα | mAb | Approved | QUEST | T2-high asthma (elevated BEC or FeNO) |
| Tezepelumab | TSLP | mAb | Approved | NAVIGATOR | Broad phenotype |
| Depemokimab | IL-5 | Ultra-long-acting mAb | Approved | SWIFT-1/2 | Eosinophilic asthma |
| Itepekimab | IL-33 | mAb | Phase 2/3 | - | Moderate-to-severe asthma |
| Tozorakimab | IL-33 | mAb | Phase 2 | FRONTIER-3 | Early-onset asthma |
| Astegolimab | ST2 | mAb | Phase 2/3 | - | Broad phenotype |
| Verekitug | TSLP-R | Long-acting mAb | Phase 1b | - | Broad phenotype |
| Lunsekimig | TSLP+IL-13 | Bispecific mAb | Phase 1b | - | T2 asthma |
| Rilzabrutinib | BTK | Oral small molecule | Phase 2 | - | Mixed phenotype |
| Dexpramipexole | Eosinophil progenitor | Oral small molecule | Phase 2 | EXHALE | Eosinophilic asthma |
| Inhaled TSLP nanobody | TSLP | Inhaled nanobody | Preclinical/Phase 1 | - | Airway-targeted |
IgE: immunoglobulin E; mAb: monoclonal antibody; IL: interleukin; T2: type-2; BEC: blood eosinophil count; FeNO: fractional exhaled nitric oxide; TSLP: thymic stromal lymphopoietin; ST2: suppression of tumorigenicity 2; BTK: Bruton tyrosine kinase.
Current Biologics and Their Effects
1. Clinical efficacy across biomarkers
Clinical efficacy of currently approved biologics in asthma is closely linked to baseline type-2 biomarkers, particularly blood eosinophil counts (BECs) and fractional exhaled nitric oxide (FeNO), which reflect their roles in the type-2 inflammatory cascade [14]. Anti-IL-5 and anti-IL-5 receptor biologics consistently show the greatest reductions in exacerbation risk among patients with elevated BECs, underscoring the central role of eosinophils in corticosteroid-refractory type-2 asthma [15]. In pivotal trials, mepolizumab reduced annualized exacerbation rates by approximately 50% in patients with BECs of 150 to 300 cells per microliter, while attenuated effects were observed at lower eosinophil thresholds [16]. Similarly, benralizumab significantly reduced exacerbations and rapidly depleted circulating eosinophils through antibody-dependent cell-mediated cytotoxicity, with treatment effects strongly influenced by baseline eosinophil levels [17]. Biologics that target the IL-4 and IL-13 signaling axis demonstrate efficacy across a wider range of biomarkers, with clinical responses linked to both BECs and FeNO levels. In the Questionnaire for Uncontrolled Eosinophilic aSthma Treatment (LIBERTY ASTHMA QUEST) trial, dupilumab reduced severe exacerbations and improved lung function, showing the most significant benefits in patients with elevated BECs or FeNO levels [18]. However, a clear reduction in severe exacerbations was not observed in the subgroup with baseline BEC below 150 cells/μL, indicating that clinical benefits are most consistent in patients with higher type-2 biomarker levels. Omalizumab, which targets IgE-mediated allergic amplification, primarily reduces exacerbations in patients with allergic asthma, although its clinical benefit is less closely correlated with BECs compared to biologics that target downstream cytokines [19]. In contrast, tezepelumab, an antibody targeting TSLP, showed reductions in exacerbation rates across a broad spectrum of baseline BECs and FeNO levels, reinforcing the idea of upstream pathway inhibition [20]. Notably, the reduction in exacerbations with tezepelumab remained clinically significant even in patients with BECs below 300 cells per microliter, a population for which other biologics demonstrate diminished efficacy. Among biologics, improvements in FeNO tend to be most pronounced with agents targeting IL-4 and IL-13 signaling or upstream epithelial cytokines, which reflects their direct effects on nitric oxide synthase expression in the airway epithelium [21].
2. Limitations of current biologic strategies
Despite substantial advances, current biologic therapies for asthma are primarily optimized for type-2-high disease and demonstrate the greatest clinical efficacy in patients with elevated BECs or related biomarkers [22]. Pivotal trials of anti-IL-5 and anti-IL-5 receptor biologics consistently show a significant reduction in exacerbations correlated with baseline eosinophil levels, revealing diminished benefits in patients with low eosinophil counts [16]. In addition, near-complete depletion of circulating eosinophils does not consistently lead to clinical remission, indicating that merely suppressing eosinophils may not be enough to control all disease-driving pathways [23]. These observations indicate a fundamental limitation of downstream cytokine targeting: clinical response depends on the dominance of a specific inflammatory effector rather than on the full spectrum of disease biology [24].
In patients with non-type-2 asthma, who often have low eosinophil counts and normal FeNO levels, current biologics often do not achieve significant reductions in exacerbations or symptom burden [25]. Moreover, non-type-2 asthma includes a variety of mechanisms, such as neutrophilic inflammation, epithelial dysfunction, and dysregulated innate immune responses, none of which are directly addressed by current biologic agents. Even in patients classified as type-2-high, incomplete responses to biologics are common, with residual exacerbations persisting despite the suppression of the targeted pathway [26]. These residual events may stem from parallel or upstream inflammatory pathways, including epithelial-derived signaling that remains active even with downstream blockade.
Residual Pathways Driving Exacerbations Despite Biologic Therapy
1. Why residual exacerbations persist
Acute exacerbations continue to be a significant factor influencing morbidity, healthcare utilization, and mortality in asthma, even in the era of biologic therapies aimed at targeting type-2 inflammation [1]. Randomized trials of biologics consistently show significant reductions, though not complete elimination, of exacerbation risk. This indicates that residual disease activity remains despite effective suppression of targeted pathways [27]. Across anti-IL-5, anti-IL-5 receptor, anti-IL-4Rα, and anti-IgE therapies, a clinically meaningful proportion of patients continues to experience moderate-to-severe exacerbations during treatment [28]. These breakthrough exacerbations are significant events, as they are linked to accelerated lung function decline, increased systemic corticosteroid exposure, and a heightened risk of adverse long-term outcomes [29]. Importantly, residual exacerbations occur not only in patients with low baseline type-2 biomarkers but also in those with initially eosinophilic disease who achieve significant biomarker suppression on biologic therapy [30]. This observation suggests that factors beyond classical eosinophil-driven inflammation contribute to asthma instability, indicating that exacerbations may result from mechanisms not fully addressed by current biologics. Respiratory viral infections, environmental pollutants, and epithelial barrier dysfunction are common triggers of residual exacerbations, often acting through non-type-2 or mixed inflammatory pathways [31]. In this context, the persistence of exacerbations despite biologic therapy does not indicate therapeutic failure; rather, it reflects the intrinsic biological heterogeneity of asthma. Clinically, these residual exacerbations require focused attention, as they identify patients at ongoing risk who may benefit from alternative or complementary strategies beyond single-pathway biologic inhibition.
2. Transcriptomic evidence of epithelial-driven exacerbation mechanisms
Recent transcriptomic analyses have identified molecular pathways underlying asthma exacerbations that persist even with effective suppression of type-2 inflammation [32]. Transcriptomic profiling of peripheral blood has revealed distinct asthma endotypes characterized by heterogeneous immune profiles, which include both type-2 and non-type-2 patterns [33]. The Mechanisms Underlying Pneumococcal and other resPiratory Infections in The Severely Asthmatic—Study 2 (MUPPITS-2) trial included longitudinal nasal RNA sequencing in children and adolescents with severe asthma treated with mepolizumab. The results showed that exacerbations continued despite significant reductions in eosinophils and type-2 biomarkers [34]. Consistent with these findings, a transcriptome network analysis identified epithelial-associated SMAD3 signaling as a key early event in both virus-associated and nonviral asthma exacerbations in children, functioning independently of type-2 inflammatory pathways [35]. Gene expression profiling showed that a SMAD3-centered module, which is enriched with transforming growth factor-β1 (TGF-β1)–induced transcription factors and genes related to wound healing and epithelial differentiation, was upregulated within the first day of exacerbation onset and remained elevated throughout the event. This epithelial response is further supported by in vitro evidence indicating that TGF-β1 triggers Smad3-dependent epithelial–mesenchymal transition in primary airway epithelial cells from asthma patients, establishing a connection between Smad3 activation and impaired epithelial repair [36].
3. Clinical implications of epithelial-driven inflammation
Epithelial-driven inflammation shifts the clinical focus from static inflammatory phenotypes to dynamic processes that involve barrier integrity, injury responses, and host-environment interactions, especially during viral and environmental insults. This perspective challenges the current paradigm, which primarily defines biologic success by the reduction of exacerbations, and instead views residual exacerbations as indicators of unresolved epithelial mechanisms. These insights advocate for expanding therapeutic strategies beyond just targeting downstream cytokines to include epithelial signaling and repair pathways. Additionally, there is a need for biomarker approaches that reflect epithelial activity. By integrating epithelial biology into clinical decision-making, we may enhance the identification of patients at risk for recurrent exacerbations and guide the development of therapies that improve airway stability.
Emerging New Biologics Targeting Upstream and Non-Type-2 Pathways
1. IL-33 and ST2 axis
IL-33 is an epithelial-derived alarmin released in response to environmental injury, viral infection, and mechanical stress. It signals through its receptor suppression of tumorigenicity 2 (ST2), activating both innate and adaptive immune responses that are implicated in asthma exacerbations [37]. Unlike downstream type-2 cytokines, IL-33 occupies an upstream position in the inflammatory cascade, amplifying airway inflammation independently of baseline eosinophil levels or IgE-mediated sensitization [38].
Itepekimab, a monoclonal antibody that targets IL-33, was evaluated in a phase 2 randomized trial involving patients with moderate-to-severe asthma who were receiving medium- or high-dose ICSs. The primary endpoint was defined as the loss of asthma control [39]. In this study, itepekimab significantly reduced the risk of losing asthma control compared to placebo, while the combination therapy of itepekimab and dupilumab did not provide any additional benefit. Utilizing loss of asthma control as a composite endpoint—which includes lung function decline, increased rescue medication use, and exacerbations—reflects a shift toward capturing dynamic disease instability rather than focusing solely on isolated severe events [40].
Tozorakimab, an IL-33-targeting antibody, was evaluated in a phase 2a trial (First Randomised cOntrolled study of toNozorakimab in TargetIng Early-onset as-tRhma—Study 3 [FRONTIER-3]) involving adults with uncontrolled early-onset asthma, with the change in pre-bronchodilator FEV1 as the primary endpoint [41]. FRONTIER-3 did not meet its primary endpoint, as tozorakimab did not show a statistically significant improvement in clinic-measured pre-bronchodilator FEV1 compared to placebo at week 16. However, exploratory analyses indicated numerical improvements in lung function and symptom-related outcomes among patients with a history of at least two exacerbations in the preceding 12 months. This subgroup may represent a more responsive population, despite predominantly low baseline BECs. Astegolimab, an antibody targeting ST2, the IL-33 receptor, was evaluated in a 52-week phase 2 trial that used exacerbation rate as the primary endpoint in patients with moderate-to-severe asthma [42]. Astegolimab reduced annualized exacerbation rates compared to placebo, with treatment effects observed across eosinophil strata. This supports the idea that IL-33-ST2 signaling contributes to asthma activity beyond classical type-2 inflammation.
Targeting the IL-33-ST2 axis can modulate asthma instability through upstream mechanisms. Moreover, endpoints such as loss of asthma control may better capture the clinical relevance of these interventions than exacerbation frequency alone [43].
2. Bruton tyrosine kinase pathway inhibition
BTK is a central signaling molecule found in various immune cell lineages, including B cells, mast cells, macrophages, and neutrophils. It integrates signals from both antigen receptors and Fc receptors [44]. In mast cells, BTK is essential for Fc epsilon receptor I (FcεRI)-mediated degranulation and cytokine release, connecting allergen exposure to immediate hypersensitivity reactions and subsequent inflammatory amplification [45]. In B cells, BTK regulates B-cell receptor signaling, antibody production, and antigen presentation, thereby influencing adaptive immune responses related to allergic sensitization and chronic airway inflammation [46]. Beyond lymphoid cells, BTK signaling in macrophages and myeloid cells modulates Fc receptor-mediated phagocytosis, cytokine production, and innate immune activation—processes that are increasingly recognized in non-type-2 asthma phenotypes [47].
Rilzabrutinib is an oral, reversible BTK inhibitor designed to offer systemic immunomodulation without the need for parenteral administration, setting it apart from injectable biologic therapies [48]. In preclinical and early clinical studies, rilzabrutinib inhibited mast cell activation, reduced antibody-dependent cellular responses, and attenuated macrophage-driven inflammation, highlighting its potential utility in both allergic and non-type-2 pathways [49]. A phase 2 randomized controlled trial evaluated rilzabrutinib in patients with moderate-to-severe asthma. Preliminary data presented in abstract form indicated trends toward reduced loss of asthma control and rapid improvement in symptom-based outcomes, although these findings are pending full peer-reviewed publication [50]. Notably, clinical responses to rilzabrutinib were observed without strict dependence on BECs, indicating its effectiveness in disease areas not sufficiently addressed by eosinophil-targeted biologics. The oral route of administration may further improve treatment accessibility and adherence, especially for patients who are hesitant to start injectable biologic therapies or who exhibit mixed inflammatory phenotypes.
BTK inhibition represents a distinct mechanistic approach that connects innate and adaptive immunity, providing a complementary strategy for patients whose asthma remains uncontrolled despite optimized inhaled therapy and conventional biologics.
3. Eosinophil lineage targeting
Eosinophils are central to the pathobiology of type-2-high asthma, contributing to airway inflammation, increasing the risk of exacerbations, and influencing corticosteroid responsiveness [51]. Current eosinophil-targeted biologics, including antibodies against IL-5 or its receptor, primarily target mature circulating eosinophils and tissue-resident cells by disrupting their survival and activation signals [52]. Although these agents lead to significant reductions in BECs and exacerbation rates, some patients may still experience residual eosinophilic inflammation, indicating ongoing eosinophil production in the bone marrow.
Dexpramipexole offers a distinct mechanistic approach by selectively inhibiting eosinophil lineage commitment and maturation in the bone marrow, rather than targeting downstream cytokine signaling. It suppresses early eosinophil progenitors and reduces the synthesis of eosinophil granule proteins, while having minimal effects on other myeloid lineages [53]. In a phase 2 randomized trial involving patients with asthma and elevated BECs, oral dexpramipexole resulted in dose-dependent reductions in circulating eosinophils over 12 weeks of treatment [54]. Importantly, reductions in eosinophil counts were accompanied by decreases in eosinophil peroxidase levels and modest improvements in lung function, indicating a biologically significant effect on eosinophil-driven airway disease. Unlike anti-IL-5 therapies, which rely on sustained cytokine blockade to maintain eosinophil suppression, dexpramipexole directly limits eosinophil supply by reducing upstream production [53].
4. Inhaled biologics and nanobody concepts
Conventional monoclonal antibody biologics are administered systemically and can achieve therapeutic effects in the airways, even with limited tissue penetration and prolonged systemic exposure [55,56]. Nanobodies are single-domain antibody fragments derived from heavy-chain-only antibodies. They are approximately one-tenth the size of conventional IgG molecules, which provides enhanced tissue penetration and stability [57]. Their small molecular size and high solubility allow for efficient diffusion within the airway mucosa, providing access to epithelial and subepithelial compartments that may be less accessible to full-length antibodies [58]. Inhaled delivery of biologics enhances these advantages by directly targeting the respiratory tract, maximizing local drug concentrations while minimizing systemic exposure [59]. Reduced systemic exposure is particularly important for biologic therapies, as it may lower the risk of off-target immune effects and enhance long-term safety profiles.
TSLP has emerged as a compelling target for inhaled biologic strategies due to its predominant expression by airway epithelial cells and its upstream role in orchestrating multiple inflammatory pathways [60]. Preclinical studies of inhaled nanobodies targeting TSLP have shown significant reductions in airway eosinophilia, suppression of chemokine expression, and a decrease in lung inflammation in experimental asthma models [61]. Histopathologic analyses in these models revealed decreased inflammatory cell infiltration and improved airway architecture following the administration of inhaled nanobodies, supporting effective local immune modulation. Unlike systemic TSLP blockade, inhaled nanobody approaches may preferentially target epithelial-driven inflammation at the site of cytokine release, potentially preserving systemic immune function [62].
However, the inflamed airway environment is characterized by elevated protease activity and varying mucus levels, which may pose challenges to the stability and uniform distribution of inhaled biologics [63].
Long-Acting and Ultra-Long-Acting Biologics
1. Rationale for extended dosing intervals
Long-term disease control in severe asthma necessitates sustained suppression of inflammatory activity. However, real-world outcomes frequently diverge from those observed in randomized trials due to suboptimal treatment persistence and adherence [64]. Even after initiating biologic treatment, discontinuation and delayed dosing are common in routine practice. This is largely due to the treatment burden associated with frequent injections, clinic visits, and logistical complexities [65]. Extended dosing intervals offer a practical approach to reducing treatment burden while preserving pharmacologic activity. This strategy is made possible by advancements in antibody engineering that enhance prolonged half-life and ensure sustained target engagement [66]. Improved dosing convenience is associated with better adherence and persistence across chronic diseases [67], and in asthma, sustained treatment exposure is linked to fewer exacerbations and reduced health care utilization [68].
2. Long-acting IL-5 pathway inhibition
Depemokimab (Exdensur, GlaxoSmithKline, London, UK) is an ultra-long-acting monoclonal antibody targeting IL-5, approved by the U.S. Food and Drug Administration in December 2025 as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype. It is designed to achieve prolonged target engagement with dosing intervals of 6 months. In two phase 3 randomized controlled trials (Study With depemokImab For Twice-yearly dosing—Study 1/Study 2 [SWIFT-1/2]) involving patients with severe eosinophilic asthma, depemokimab significantly reduced annualized exacerbation rates and the risk of severe exacerbations compared to placebo over a 52-week period [69]. However, no statistically significant differences in health-related quality of life, as measured by the St. George's Respiratory Questionnaire, were observed between groups in either trial. Notably, subgroup analyses showed that the magnitude of exacerbation reduction did not exhibit a clear gradient across baseline blood eosinophil strata, which contrasts with the patterns observed with earlier anti-IL-5 biologics. This apparent attenuation of eosinophil-dependent response variability may indicate continuous and near-complete suppression of circulating IL-5 over extended periods, thereby minimizing fluctuations in eosinophil biology between doses.
Alternatively, the absence of a strong BEC-response gradient raises questions about the adequacy of BECs as a surrogate for tissue-level eosinophilic activity during prolonged cytokine blockade. Previous studies with shorter-acting anti-IL-5 agents, such as mepolizumab, consistently demonstrated greater clinical benefits at higher eosinophil thresholds, highlighting the novelty of the response pattern observed with depemokimab [70]. From a clinical perspective, ultra-long-acting IL-5 inhibition may enhance treatment persistence and real-world effectiveness; however, it complicates traditional biomarker-guided patient selection strategies. Consequently, depemokimab raises questions about whether BECs alone can reliably predict responses to IL-5-targeted therapies, highlighting the need for more refined biomarkers of treatment effect.
3. Long-acting TSLP pathway inhibition
TSLP is an epithelial-derived cytokine that plays a central role in the inflammatory cascade. It integrates signals from allergens, viruses, and environmental injuries to initiate downstream immune activation [60]. Systemic blockade of TSLP with tezepelumab has shown significant reductions in asthma exacerbations across various biomarker profiles, confirming TSLP as a clinically relevant upstream therapeutic target [20]. These findings have sparked interest in extending upstream TSLP inhibition with long-acting formulations that can sustain target suppression while reducing dosing frequency. Verekitug (Upstream Bio, Waltham, MA, USA) is a long-acting monoclonal antibody that targets the TSLP receptor and has been engineered to provide prolonged pharmacodynamic effects with infrequent administration. In a phase 1 study, verekitug showed sustained suppression of circulating biomarkers associated with TSLP signaling, including reductions in BECs and FeNO [71]. Pharmacodynamic effects were sustained over extended intervals after dosing, highlighting the feasibility of long-acting inhibition of the upstream pathway. The lack of short-term safety signals in early clinical testing is encouraging; however, longer follow-up and larger populations are necessary to fully characterize the safety profile of sustained TSLP pathway suppression.
From a mechanistic standpoint, long-acting inhibition of the TSLP pathway may provide advantages over downstream cytokine targeting by continuously attenuating multiple inflammatory pathways, including both type-2 and non-type-2 responses [72]. This approach may be especially relevant for patients with fluctuating biomarker profiles or mixed inflammatory phenotypes, as intermittent pathway reactivation could undermine disease control when using shorter-acting agents [73]. However, the clinical implications of prolonged upstream immune modulation remain uncertain. Careful evaluation is needed to balance durable efficacy with potential effects on host defense and immune homeostasis.
Combination and Bispecific Biologic Strategies
1. Lessons from previous combination approaches
The success of multiple biologics targeting distinct inflammatory pathways in asthma has led to the hypothesis that combining these agents could provide additive or synergistic clinical benefits. This idea is especially appealing for patients with persistent disease activity, where an incomplete response to single-pathway inhibition is often seen as evidence of parallel inflammatory drivers. However, the randomized phase 2 trial evaluating the combination of itepekimab and dupilumab offered a crucial empirical test of this concept under controlled conditions [39]. In this study, patients receiving medium-to-high doses of ICS and LABA were assigned to either itepekimab, dupilumab, their combination, or a placebo, with a protocolized withdrawal of inhaled therapy designed to provoke loss of asthma control. Both itepekimab and dupilumab monotherapy significantly reduced the risk of loss of asthma control compared to placebo; however, the combination of itepekimab and dupilumab did not provide any additional benefit beyond either agent alone. Notably, the combination arm exhibited numerically higher rates of loss of asthma control than the monotherapy arms, suggesting that simultaneous blockade of upstream and downstream type-2 pathways did not result in additive protection. Similar patterns were observed for lung function outcomes, with improvements in pre-bronchodilator FEV1 seen with monotherapy but not enhanced by combination treatment. From a biological perspective, the lack of additivity is understandable, as dupilumab already provides broad suppression of type-2 effector signaling by inhibiting IL-4 and IL-13 pathways. This may limit the incremental impact of additional upstream blockade. Furthermore, the itepekimab trial indicates that targeting multiple points within the same inflammatory axis may lead to biological redundancy or ceiling effects, rather than yielding cumulative clinical benefits. These findings challenge the assumption that a nonresponse to a biologic necessarily signifies insufficient pathway coverage. Instead, they suggest that residual disease activity may stem from orthogonal mechanisms not addressed by simple pathway stacking [74]. Clinically, the lack of additive benefit of the itepekimab and dupilumab combination therapy highlights the importance of strategically sequencing or switching currently available biologics, rather than relying on empirical combinations, when patients exhibit a suboptimal response.
2. Bispecific biologics
The limitations of targeting individual inflammatory pathways and the complexity of asthma biology have led to increased interest in bispecific and multispecific antibodies. These antibodies are designed to integrate multiple inflammatory signals within a single molecular construct. Bispecific biologics may provide advantages over traditional combination therapy by ensuring coordinated target engagement, synchronized pharmacokinetics, and minimizing redundant or competing pathway blockade [75]. In asthma, combining the inhibition of TSLP with downstream type-2 effector cytokines, such as interleukin-13, represents a rational strategy to target both epithelial-derived triggers and airway effector mechanisms [76].
Lunsekimig is a bispecific monoclonal antibody designed to simultaneously neutralize TSLP and IL-13, integrating upstream epithelial signaling with downstream type-2 effector blockade. In a phase 1b study, lunsekimig demonstrated acceptable safety and tolerability, with pharmacodynamic effects that align with the inhibition of both TSLP and IL-13 signaling pathways [77]. Lunsekimig reduced biomarkers associated with type-2 inflammation, including FeNO and BECs, suggesting effective engagement of downstream pathways. Importantly, simultaneous inhibition of both upstream and downstream pathways may help mitigate the reactivation of epithelial-driven inflammatory programs that persist under single-pathway blockade. From a translational perspective, bispecific biologics could overcome the biological ceiling observed with combination therapy by providing integrated signaling suppression instead of merely additive pathway inhibition. However, the long-term clinical efficacy, safety, and patient selection criteria for bispecific strategies like lunsekimig still need to be established in phase 2 and phase 3 trials.
Conclusion
Biologic therapies have transformed asthma management by enabling mechanism-based interventions, resulting in substantial reductions in exacerbations, improved lung function, and decreased dependence on corticosteroids. However, breakthrough exacerbations remain common, indicating residual disease activity that current biologic strategies do not fully address. The development of long-acting, ultra-long-acting, and bispecific biologics reflects a shift toward sustained pathway suppression and improved treatment durability. Emerging evidence suggests that epithelial stress responses, innate immune activation, and tissue repair pathways contribute to persistent disease instability beyond classical type-2 inflammation. These findings highlight the airway epithelium as a central driver of asthma heterogeneity and therapeutic response. Future advances will rely on strategies that extend beyond downstream cytokine blockade to include upstream epithelial targets, lineage-specific approaches, and multispecific biologics.
Footnotes
Conflicts of Interest
Hyun Woo Lee is an early career editorial board member of the journal, but he was not involved in the peer reviewer selection, evaluation, or decision process of this article.
Funding
No funding to declare.
REFERENCES
- 1.Papi A, Brightling C, Pedersen SE, Reddel HK. Asthma. Lancet. 2018;391:783–800. doi: 10.1016/S0140-6736(17)33311-1. [DOI] [PubMed] [Google Scholar]
- 2.Bae E, Park HJ, Park H, Lee JK, Heo EY, Lee CH, et al. Early clinical remission and its role in lung function decline and exacerbation in adult Korean patients with asthma. Thorax. 2025;80:273–82. doi: 10.1136/thorax-2024-222679. [DOI] [PubMed] [Google Scholar]
- 3.Park HJ, Lee CH, Lee JK, Kim DK, Lee HW. Clinical remission at two years post-diagnosis of asthma and its association with clinical outcomes: a retrospective cohort study in asthma patients with maintenance inhaler therapy. Pulm Pharmacol Ther. 2025;90:102381. doi: 10.1016/j.pupt.2025.102381. [DOI] [PubMed] [Google Scholar]
- 4.Gyawali B, Georas SN, Khurana S. Biologics in severe asthma: a state-of-the-art review. Eur Respir Rev. 2025;34:240088. doi: 10.1183/16000617.0088-2024. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Bhalla A, Zhao N, Rivas DD, Ho T, Perez de Llano L, Mukherjee M, et al. Exacerbations of severe asthma while on anti-IL-5 biologics. J Investig Allergol Clin Immunol. 2020;30:307–16. doi: 10.18176/jiaci.0628. [DOI] [PubMed] [Google Scholar]
- 6.Varut RM, Dalia D, Radivojevic K, Trasca DM, Stoica GA, Adrian NS, et al. Targeted biologic therapies in severe asthma: mechanisms, biomarkers, and clinical applications. Pharmaceuticals (Basel) 2025;18:1021. doi: 10.3390/ph18071021. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kim SR. Next-generation therapeutic approaches for uncontrolled asthma: insights into the heterogeneity of non-type 2 inflammation. Allergy Asthma Immunol Res. 2024;16:1–5. doi: 10.4168/aair.2024.16.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Alska E, Laszczych D, Napiorkowska-Baran K, Szymczak B, Rajewska A, Rubisz AE, et al. Advances in biologic therapies for allergic diseases: current trends, emerging agents, and future perspectives. J Clin Med. 2025;14:1079. doi: 10.3390/jcm14041079. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012;367:1198–207. doi: 10.1056/NEJMoa1208606. [DOI] [PubMed] [Google Scholar]
- 10.Papi A, Fabbri LM, Kerstjens HA, Rogliani P, Watz H, Singh D. Inhaled long-acting muscarinic antagonists in asthma: a narrative review. Eur J Intern Med. 2021;85:14–22. doi: 10.1016/j.ejim.2021.01.027. [DOI] [PubMed] [Google Scholar]
- 11.Rogliani P, Ritondo BL, Calzetta L. Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. Eur Respir J. 2021;58:2004233. doi: 10.1183/13993003.04233-2020. [DOI] [PubMed] [Google Scholar]
- 12.Lee LA, Bailes Z, Barnes N, Boulet LP, Edwards D, Fowler A, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9:69–84. doi: 10.1016/S2213-2600(20)30389-1. [DOI] [PubMed] [Google Scholar]
- 13.McCracken JL, Tripple JW, Calhoun WJ. Biologic therapy in the management of asthma. Curr Opin Allergy Clin Immunol. 2016;16:375–82. doi: 10.1097/ACI.0000000000000284. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Israel E, Wechsler ME, Jackson DJ, Moore WC. Anticytokine biologics for asthma in adults. Lancet. 2025;406:2282–94. doi: 10.1016/S0140-6736(25)01625-3. [DOI] [PubMed] [Google Scholar]
- 15.Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371:1198–207. doi: 10.1056/NEJMoa1403290. [DOI] [PubMed] [Google Scholar]
- 16.Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–9. doi: 10.1016/S0140-6736(12)60988-X. [DOI] [PubMed] [Google Scholar]
- 17.Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376:2448–58. doi: 10.1056/NEJMoa1703501. [DOI] [PubMed] [Google Scholar]
- 18.Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378:2486–96. doi: 10.1056/NEJMoa1804092. [DOI] [PubMed] [Google Scholar]
- 19.Humbert M, Busse W, Hanania NA, Lowe PJ, Canvin J, Erpenbeck VJ, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014;2:525–36.e1. doi: 10.1016/j.jaip.2014.03.010. [DOI] [PubMed] [Google Scholar]
- 20.Menzies-Gow A, Corren J, Bourdin A, Chupp G, Israel E, Wechsler ME, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021;384:1800–9. doi: 10.1056/NEJMoa2034975. [DOI] [PubMed] [Google Scholar]
- 21.Rolla G, Heffler E, Pizzimenti S, Michils A, Malinovschi A. An emerging role for exhaled nitric oxide in guiding biological treatment in severe asthma. Curr Med Chem. 2020;27:7159–67. doi: 10.2174/0929867327666200713184659. [DOI] [PubMed] [Google Scholar]
- 22.Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–25. doi: 10.1038/nm.2678. [DOI] [PubMed] [Google Scholar]
- 23.Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting b2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–27. doi: 10.1016/S0140-6736(16)31324-1. [DOI] [PubMed] [Google Scholar]
- 24.Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine. Allergol Int. 2016;65:243–52. doi: 10.1016/j.alit.2016.04.011. [DOI] [PubMed] [Google Scholar]
- 25.Esteban-Gorgojo I, Antolin-Amerigo D, Dominguez-Ortega J, Quirce S. Non-eosinophilic asthma: current perspectives. J Asthma Allergy. 2018;11:267–81. doi: 10.2147/JAA.S153097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Siddiqui S, Denlinger LC, Fowler SJ, Akuthota P, Shaw DE, Heaney LG, et al. Unmet needs in severe asthma subtyping and precision medicine trials: bridging clinical and patient perspectives. Am J Respir Crit Care Med. 2019;199:823–9. doi: 10.1164/rccm.201809-1817PP. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Kyriakopoulos C, Gogali A, Markozannes G, Kostikas K. Biologic agents licensed for severe asthma: a systematic review and meta-analysis of randomised controlled trials. Eur Respir Rev. 2024;33:230238. doi: 10.1183/16000617.0238-2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Tan R, Liew MF, Lim HF, Leung BP, Wong WS. Promises and challenges of biologics for severe asthma. Biochem Pharmacol. 2020;179:114012. doi: 10.1016/j.bcp.2020.114012. [DOI] [PubMed] [Google Scholar]
- 29.O'Byrne PM, Pedersen S, Lamm CJ, Tan WC, Busse WW, START Investigators Group Severe exacerbations and decline in lung function in asthma. Am J Respir Crit Care Med. 2009;179:19–24. doi: 10.1164/rccm.200807-1126OC. [DOI] [PubMed] [Google Scholar]
- 30.McDowell PJ, Redmond C, Busby J, Patel P, Jackson DJ, Pfeffer PE, et al. Observational analysis of biological remission as a treatment target for severe asthma: UK severe asthma registry. J Allergy Clin Immunol Pract. 2025;13:3264–73.e10. doi: 10.1016/j.jaip.2025.08.027. [DOI] [PubMed] [Google Scholar]
- 31.Cecchi L, Vaghi A, Bini F, Martini M, Musarra A, Bilo MB. From triggers to asthma: a narrative review on epithelium dysfunction. Eur Ann Allergy Clin Immunol. 2022;54:247–57. doi: 10.23822/EurAnnACI.1764-1489.271. [DOI] [PubMed] [Google Scholar]
- 32.Liu T, Woodruff PG, Zhou X. Advances in non-type 2 severe asthma: from molecular insights to novel treatment strategies. Eur Respir J. 2024;64:2300826. doi: 10.1183/13993003.00826-2023. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Lee HW, Baek MG, Choi S, Ahn YH, Bang JY, Sohn KH, et al. Peripheral blood transcriptomic clusters uncovered immune phenotypes of asthma. Respir Res. 2022;23:237. doi: 10.1186/s12931-022-02156-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Wilson GE, Knight J, Liu Q, Shelar A, Stewart E, Wang X, et al. Activated sputum eosinophils associated with exacerbations in children on mepolizumab. J Allergy Clin Immunol. 2024;154:297–307.e13. doi: 10.1016/j.jaci.2024.01.031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Altman MC, Gill MA, Whalen E, Babineau DC, Shao B, Liu AH, et al. Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children. Nat Immunol. 2019;20:637–51. doi: 10.1038/s41590-019-0347-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Hackett TL, Warner SM, Stefanowicz D, Shaheen F, Pechkovsky DV, Murray LA, et al. Induction of epithelial-mesenchymal transition in primary airway epithelial cells from patients with asthma by transforming growth factor-beta1. Am J Respir Crit Care Med. 2009;180:122–33. doi: 10.1164/rccm.200811-1730OC. [DOI] [PubMed] [Google Scholar]
- 37.Cayrol C, Girard JP. Interleukin-33 (IL-33): a nuclear cytokine from the IL-1 family. Immunol Rev. 2018;281:154–68. doi: 10.1111/imr.12619. [DOI] [PubMed] [Google Scholar]
- 38.Lloyd CM. IL-33 family members and asthma: bridging innate and adaptive immune responses. Curr Opin Immunol. 2010;22:800–6. doi: 10.1016/j.coi.2010.10.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Wechsler ME, Ruddy MK, Pavord ID, Israel E, Rabe KF, Ford LB, et al. Efficacy and safety of itepekimab in patients with moderate-to-severe asthma. N Engl J Med. 2021;385:1656–68. doi: 10.1056/NEJMoa2024257. [DOI] [PubMed] [Google Scholar]
- 40.Reddel HK, Taylor DR, Bateman ED, Boulet LP, Boushey HA, Busse WW, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. doi: 10.1164/rccm.200801-060ST. [DOI] [PubMed] [Google Scholar]
- 41.Corren J, Reid F, Moate R, Jimenez E, Sadiq MW, Williams A, et al. FRONTIER-3: a randomised phase 2a study to investigate tozorakimab, an anti-interleukin-33 monoclonal antibody, in early-onset asthma. ERJ Open Res. 2026;12:00183–2025. doi: 10.1183/23120541.00183-2025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Kelsen SG, Agache IO, Soong W, Israel E, Chupp GL, Cheung DS, et al. Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: a randomized clinical trial. J Allergy Clin Immunol. 2021;148:790–8. doi: 10.1016/j.jaci.2021.03.044. [DOI] [PubMed] [Google Scholar]
- 43.Sheng F, Li M, Yu JM, Yang SY, Zou L, Yang GJ, et al. IL-33/ST2 axis in diverse diseases: regulatory mechanisms and therapeutic potential. Front Immunol. 2025;16:1533335. doi: 10.3389/fimmu.2025.1533335. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Gundrathi SG, Sanapalli BK, Palit S, Sigalapalli DK, Deshpande A, Sanapalli V. Bruton's tyrosine kinase: pathophysiological roles and inhibitor-based therapeutic advances. Cell Biochem Funct. 2026;44:e70174. doi: 10.1002/cbf.70174. [DOI] [PubMed] [Google Scholar]
- 45.Hata D, Kawakami Y, Inagaki N, Lantz CS, Kitamura T, Khan WN, et al. Involvement of Bruton's tyrosine kinase in FcepsilonRI-dependent mast cell degranulation and cytokine production. J Exp Med. 1998;187:1235–47. doi: 10.1084/jem.187.8.1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Satterthwaite AB, Witte ON. The role of Bruton's tyrosine kinase in B-cell development and function: a genetic perspective. Immunol Rev. 2000;175:120–7. [PubMed] [Google Scholar]
- 47.Weber ANR, Bittner Z, Liu X, Dang TM, Radsak MP, Brunner C. Bruton's tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454. doi: 10.3389/fimmu.2017.01454. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: advancing beyond approved novel step-up therapies for asthma. Ann Allergy Asthma Immunol. 2025;134:9–18. doi: 10.1016/j.anai.2024.09.016. [DOI] [PubMed] [Google Scholar]
- 49.Lin EV, Arce B, Alvarez-Arango S, Dispenza MC. Current and future landscape of Bruton tyrosine kinase inhibitors in allergy. J Allergy Clin Immunol. 2025;156:568–78. doi: 10.1016/j.jaci.2025.05.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Laidlaw TM, Maspero JF, Pavord ID, Busse WW, Liu T, Martincova R, et al. Efficacy and safety of rilzabrutinib–a novel oral treatment in asthma: results from a double blind placebo controlled phase 2 study. Am J Respir Crit Care Med. 2024;209(Suppl 1):A7002. [Google Scholar]
- 51.Hussain M, Liu G. Eosinophilic asthma: pathophysiology and therapeutic horizons. Cells. 2024;13:384. doi: 10.3390/cells13050384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Lombardi C, Berti A, Cottini M. The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions. Curr Res Immunol. 2022;3:42–53. doi: 10.1016/j.crimmu.2022.03.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Dworetzky SI, Hebrank GT, Archibald DG, Reynolds IJ, Farwell W, Bozik ME. The targeted eosinophil-lowering effects of dexpramipexole in clinical studies. Blood Cells Mol Dis. 2017;63:62–5. doi: 10.1016/j.bcmd.2017.01.008. [DOI] [PubMed] [Google Scholar]
- 54.Siddiqui S, Wenzel SE, Bozik ME, Archibald DG, Dworetzky SI, Mather JL, et al. Safety and Efficacy of Dexpramipexole in Eosinophilic Asthma (EXHALE): a randomized controlled trial. J Allergy Clin Immunol. 2023;152:1121–30.e10. doi: 10.1016/j.jaci.2023.05.014. [DOI] [PubMed] [Google Scholar]
- 55.Cruz E, Kayser V. Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy. Biologics. 2019;13:33–51. doi: 10.2147/BTT.S166310. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68:158–66. doi: 10.1016/j.alit.2019.01.004. [DOI] [PubMed] [Google Scholar]
- 57.Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775–97. doi: 10.1146/annurev-biochem-063011-092449. [DOI] [PubMed] [Google Scholar]
- 58.Steeland S, Vandenbroucke RE, Libert C. Nanobodies as therapeutics: big opportunities for small antibodies. Drug Discov Today. 2016;21:1076–113. doi: 10.1016/j.drudis.2016.04.003. [DOI] [PubMed] [Google Scholar]
- 59.Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67–74. doi: 10.1038/nrd2153. [DOI] [PubMed] [Google Scholar]
- 60.Ziegler SF, Artis D. Sensing the outside world: TSLP regulates barrier immunity. Nat Immunol. 2010;11:289–93. doi: 10.1038/ni.1852. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 61.Zhu M, Ma L, Gai J, Li G, Huang J, Li X, et al. Preclinical and phase I randomized study of a potent inhalable nanobody targeting TSLP for the treatment of airway inflammation. J Allergy Clin Immunol. 2025;156:1314–27.e7. doi: 10.1016/j.jaci.2025.06.024. [DOI] [PubMed] [Google Scholar]
- 62.Ziegler SF. Thymic stromal lymphopoietin and allergic disease. J Allergy Clin Immunol. 2012;130:845–52. doi: 10.1016/j.jaci.2012.07.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Tyrrell J, Tarran R. Gaining the upper hand on pulmonary drug delivery. J Pharmacovigil. 2014;2:118. doi: 10.4172/2329-6887.1000118. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Engelkes M, Janssens HM, de Jongste JC, Sturkenboom MC, Verhamme KM. Medication adherence and the risk of severe asthma exacerbations: a systematic review. Eur Respir J. 2015;45:396–407. doi: 10.1183/09031936.00075614. [DOI] [PubMed] [Google Scholar]
- 65.Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin North Am. 2005;25:107–30. doi: 10.1016/j.iac.2004.09.005. [DOI] [PubMed] [Google Scholar]
- 66.Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93:2645–68. doi: 10.1002/jps.20178. [DOI] [PubMed] [Google Scholar]
- 67.Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114–7. doi: 10.1136/bmj.39553.670231.25. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 68.Williams LK, Pladevall M, Xi H, Peterson EL, Joseph C, Lafata JE, et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J Allergy Clin Immunol. 2004;114:1288–93. doi: 10.1016/j.jaci.2004.09.028. [DOI] [PubMed] [Google Scholar]
- 69.Jackson DJ, Wechsler ME, Jackson DJ, Bernstein D, Korn S, Pfeffer PE, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med. 2024;391:2337–49. doi: 10.1056/NEJMoa2406673. [DOI] [PubMed] [Google Scholar]
- 70.Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, et al. Efficacy of mepolizumab addon therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5:390–400. doi: 10.1016/S2213-2600(17)30125-X. [DOI] [PubMed] [Google Scholar]
- 71.Singh D, Brickman CM, Lloyd P, Kalra A, Biswas S, Sinha A, et al. Verekitug, a novel antibody antagonist to the TSLP receptor in adults with asthma: a 32-week randomized phase 1b multiple ascending-dose trial. Clin Pharmacol Ther. 2026;119:782–90. doi: 10.1002/cpt.70156. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Akenroye A, Boyce JA, Kita H. Targeting alarmins in asthma: From bench to clinic. J Allergy Clin Immunol. 2025;155:1133–48. doi: 10.1016/j.jaci.2025.01.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Quek E, Horn N, Siddiqui S. Precision medicine in asthma: the role of biomarkers. Immunotargets Ther. 2025;14:1479–513. doi: 10.2147/ITT.S532291. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Coleman C, Khaleva E, Rattu A, Frankemolle B, Nielsen H, Roberts G, et al. Narrative review to capture patients' perceptions and opinions about non-response and response to biological therapy for severe asthma. Eur Respir J. 2023;61:2200837. doi: 10.1183/13993003.00837-2022. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Godar M, Deswarte K, Vergote K, Saunders M, de Haard H, Hammad H, et al. A bispecific antibody strategy to target multiple type 2 cytokines in asthma. J Allergy Clin Immunol. 2018;142:1185–93.e4. doi: 10.1016/j.jaci.2018.06.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Matera MG, Rogliani P, Calzetta L, Cazzola M. TSLP inhibitors for asthma: current status and future prospects. Drugs. 2020;80:449–58. doi: 10.1007/s40265-020-01273-4. [DOI] [PubMed] [Google Scholar]
- 77.Deiteren A, Krupka E, Bontinck L, Imberdis K, Conickx G, Bas S, et al. A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule. Eur Respir J. 2025;65:2401461. doi: 10.1183/13993003.01461-2024. [DOI] [PMC free article] [PubMed] [Google Scholar]
